Top

Published in:

01-09-2020 | Bariatric Surgery | Original Article

Association between changes in bioactive osteocalcin and glucose homeostasis after biliopancreatic diversion

Authors: Anne-Frédérique Turcotte, Thomas Grenier-Larouche, Julie Lacombe, Anne-Marie Carreau, André C. Carpentier, Fabrice Mac-Way, André Tchernof, Denis Richard, Laurent Biertho, Stefane Lebel, Simon Marceau, Mathieu Ferron, Claudia Gagnon

Published in: Endocrine | Issue 3/2020

Abstract

Purpose

Bone may regulate glucose homeostasis via uncarboxylated bioactive osteocalcin (ucOCN). This study explored whether changes in ucOCN and bone remodeling are associated with change in glucose homeostasis after biliopancreatic diversion (BPD).

Methods

In this secondary exploratory analysis of a 1-year prospective observational study, 16 participants (11 men/5 women; 69% with type 2 diabetes; mean BMI 49.4 kg/m²) were assessed before, 3 days, 3 months and 12 months after BPD. Changes in plasma ucOCN and bone markers (C-terminal telopeptide (CTX), total osteocalcin (OCN)) were correlated with changes in insulin resistance or sensitivity indices (HOMA-IR; adipose tissue insulin resistance index (ADIPO-IR) and insulin sensitivity index (SI) from the hyperinsulinemic-euglycemic clamp), insulin secretion rate (ISR) from the hyperglycemic clamp, and disposition index (DI: SI × ISR) using Spearman correlations before and after adjustment for weight loss.

Results

ucOCN was unchanged at 3 days but increased dramatically at 3 months (+257%) and 12 months (+498%). Change in ucOCN correlated significantly with change in CTX at 3 months (r = 0.62, p = 0.015) and 12 months (r = 0.64, p = 0.025) before adjustment for weight loss. It also correlated significantly with change in fasting insulin (r = −0.53, p = 0.035), HOMA-IR (r = −0.54, p = 0.033) and SI (r = 0.52, p = 0.041) at 3 days, and ADIPO-IR (r = −0.69, p = 0.003) and HbA_1c (r = −0.69, p = 0.005) at 3 months. Change in OCN did not correlate with any glucose homeostasis indices. Results were similar after adjustment for weight loss.

Conclusion

The increase in ucOCN may be associated with the improvement in insulin resistance after BPD, independently of weight loss. These findings need to be confirmed in larger, less heterogeneous populations.

G. Mingrone, S. Panunzi, A. De Gaetano, C. Guidone, A. Iaconelli, L. Leccesi, G. Nanni, A. Pomp, M. Castagneto, G. Ghirlanda, F. Rubino, Bariatric surgery versus conventional medical therapy for type 2 diabetes. N. Engl. J. Med. 366(17), 1577–1585 (2012). https://doi.org/10.1056/NEJMoa1200111CrossRefPubMed

H. Buchwald, R. Estok, K. Fahrbach, D. Banel, M.D. Jensen, W.J. Pories, J.P. Bantle, I. Sledge, Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am. J. Med. 122(3), 248–256.e245 (2009). https://doi.org/10.1016/j.amjmed.2008.09.041CrossRefPubMed

H. Buchwald, Y. Avidor, E. Braunwald, M.D. Jensen, W. Pories, K. Fahrbach, K. Schoelles, Bariatric surgery: a systematic review and meta-analysis. JAMA 292(14), 1724–1737 (2004). https://doi.org/10.1001/jama.292.14.1724CrossRefPubMed

C. Guidone, M. Manco, E. Valera-Mora, A. Iaconelli, D. Gniuli, A. Mari, G. Nanni, M. Castagneto, M. Calvani, G. Mingrone, Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55(7), 2025–2031 (2006). https://doi.org/10.2337/db06-0068CrossRefPubMed

A. Michaud, T. Grenier-Larouche, D. Caron-Dorval, S. Marceau, L. Biertho, S. Simard, D. Richard, A. Tchernof, A.C. Carpentier, Biliopancreatic diversion with duodenal switch leads to better postprandial glucose level and beta cell function than sleeve gastrectomy in individuals with type 2 diabetes very early after surgery. Metab.: Clin. Exp. 74, 10–21 (2017). https://doi.org/10.1016/j.metabol.2017.06.005CrossRef

T. Grenier-Larouche, A.M. Carreau, A. Geloen, F. Frisch, L. Biertho, S. Marceau, S. Lebel, F.S. Hould, D. Richard, A. Tchernof, A.C. Carpentier, Fatty acid metabolic remodeling during type 2 diabetes remission after bariatric surgery. Diabetes 66(11), 2743–2755 (2017). https://doi.org/10.2337/db17-0414CrossRefPubMed

T. Grenier-Larouche, A.M. Carreau, A.C. Carpentier, Early metabolic improvement after bariatric surgery: the first steps toward remission of type 2 diabetes. Can. J. Diabetes 41(4), 418–425 (2017). https://doi.org/10.1016/j.jcjd.2016.10.013CrossRefPubMed

C.E. Plourde, T. Grenier-Larouche, D. Caron-Dorval, S. Biron, S. Marceau, S. Lebel, L. Biertho, A. Tchernof, D. Richard, A.C. Carpentier, Biliopancreatic diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction. Obesity 22(8), 1838–1846 (2014). https://doi.org/10.1002/oby.20771CrossRefPubMed

C. Koliaki, S. Liatis, C.W. le Roux, A. Kokkinos, The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr. Disord. 17(1), 50 (2017). https://doi.org/10.1186/s12902-017-0202-6CrossRefPubMedPubMedCentral

10.

G. Karsenty, M. Ferron, The contribution of bone to whole-organism physiology. Nature 481(7381), 314–320 (2012). https://doi.org/10.1038/nature10763CrossRefPubMedPubMedCentral

11.

P. Mera, M. Ferron, I. Mosialou, Regulation of energy metabolism by bone-derived hormones. Cold Spring Harbor Perspect. Med. (2017). https://doi.org/10.1101/cshperspect.a031666

12.

N.K. Lee, H. Sowa, E. Hinoi, M. Ferron, J.D. Ahn, C. Confavreux, R. Dacquin, P.J. Mee, M.D. McKee, D.Y. Jung, Z. Zhang, J.K. Kim, F. Mauvais-Jarvis, P. Ducy, G. Karsenty, Endocrine regulation of energy metabolism by the skeleton. Cell 130(3), 456–469 (2007). https://doi.org/10.1016/j.cell.2007.05.047CrossRefPubMedPubMedCentral

13.

M. Ferron, E. Hinoi, G. Karsenty, P. Ducy, Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl Acad. Sci. USA 105(13), 5266–5270 (2008). https://doi.org/10.1073/pnas.0711119105CrossRefPubMedPubMedCentral

14.

J. Lacombe, G. Karsenty, M. Ferron, In vivo analysis of the contribution of bone resorption to the control of glucose metabolism in mice. Mol. Metab. 2(4), 498–504 (2013). https://doi.org/10.1016/j.molmet.2013.08.004CrossRefPubMedPubMedCentral

15.

J. Bonneau, G. Ferland, A.D. Karelis, E. Doucet, M. Faraj, R. Rabasa-Lhoret, M. Ferron, Association between osteocalcin gamma-carboxylation and insulin resistance in overweight and obese postmenopausal women. J. Diabetes Complicat. 31(6), 1027–1034 (2017). https://doi.org/10.1016/j.jdiacomp.2017.01.023CrossRef

16.

U. Razny, D. Fedak, B. Kiec-Wilk, J. Goralska, A. Gruca, A. Zdzienicka, M. Kiec-Klimczak, B. Solnica, A. Hubalewska-Dydejczyk, M. Malczewska-Malec, Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes. Diabetes/Metab. Res. Rev. 33(3), (2017). https://doi.org/10.1002/dmrr.2862

17.

Y. Takashi, M. Koga, Y. Matsuzawa, J. Saito, M. Omura, T. Nishikawa, Undercarboxylated osteocalcin can predict insulin secretion ability in type 2 diabetes. J. Diabetes Investig. 8(4), 471–474 (2017). https://doi.org/10.1111/jdi.12601CrossRefPubMedPubMedCentral

18.

Q. Guo, H. Li, L. Xu, S. Wu, H. Sun, B. Zhou, Undercarboxylated osteocalcin reverts insulin resistance induced by endoplasmic reticulum stress in human umbilical vein endothelial cells. Sci. Rep. 7(1), 46 (2017). https://doi.org/10.1038/s41598-017-00163-2CrossRefPubMedPubMedCentral

19.

D.M. Liu, X.Z. Guo, H.J. Tong, B. Tao, L.H. Sun, H.Y. Zhao, G. Ning, J.M. Liu, Association between osteocalcin and glucose metabolism: a meta-analysis. Osteoporos. Int. 26(12), 2823–2833 (2015). https://doi.org/10.1007/s00198-015-3197-8CrossRefPubMed

20.

A.F. Turcotte, T. Grenier-Larouche, R.V. Ung, D. Simonyan, A.M. Carreau, A.C. Carpentier, F. Mac-Way, L. Michou, A. Tchernof, L. Biertho, S. Lebel, S. Marceau, C. Gagnon, Effects of biliopancreatic diversion on bone turnover markers and association with hormonal factors in patients with severe obesity. Obes. Surg. 29(3), 990–998 (2019). https://doi.org/10.1007/s11695-018-3617-xCrossRefPubMed

21.

J. Lacombe, O. Al Rifai, L. Loter, T. Moran, A.F. Turcotte, T. Grenier-Larouche, A. Tchernof, L. Biertho, A.C. Carpentier, D. Prud'homme, R. Rabasa-Lhoret, G. Karsenty, C. Gagnon, W. Jiang, M. Ferron, Measurement of bioactive osteocalcin in humans using a novel immunoassay reveals association with glucose metabolism and beta-cell function. Am. J. Physiol. Endocrinol. Metab. 318(3), E381–E391 (2020). https://doi.org/10.1152/ajpendo.00321.2019CrossRefPubMedPubMedCentral

22.

Standards of Medical Care in Diabetes, Abridged for Primary Care Providers. Clin. Diabetes Publ. Am. Diabetes Assoc. 35(1), 5–26 (2017). https://doi.org/10.2337/cd16-0067

23.

L. Biertho, S. Lebel, S. Marceau, F.S. Hould, F. Julien, S. Biron, Biliopancreatic diversion with duodenal switch: surgical technique and perioperative care. Surg. Clin. N. Am. 96(4), 815–826 (2016). https://doi.org/10.1016/j.suc.2016.03.012CrossRefPubMed

24.

D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412–419 (1985)CrossRefPubMed

25.

E. Sondergaard, A.E. Espinosa De Ycaza, M. Morgan-Bathke, M.D. Jensen, How to measure adipose tissue insulin sensitivity. J. Clin. Endocrinol. Metab. 102(4), 1193–1199 (2017). https://doi.org/10.1210/jc.2017-00047CrossRefPubMedPubMedCentral

26.

A.C. Carpentier, F. Frisch, D. Cyr, P. Genereux, B.W. Patterson, R. Giguere, J.P. Baillargeon, On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans. Am. J. Physiol. Endocrinol. Metab. 289(5), E849–E856 (2005). https://doi.org/10.1152/ajpendo.00073.2005CrossRefPubMed

27.

A. Carpentier, S.D. Mittelman, B. Lamarche, R.N. Bergman, A. Giacca, G.F. Lewis, Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am. J. Physiol. 276(6 Pt 1), E1055–E1066 (1999)PubMed

28.

R.N. Bergman, M. Ader, K. Huecking, G. Van Citters, Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl 1), S212–S220 (2002)CrossRefPubMed

29.

S.E. Kahn, The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46(1), 3–19 (2003). https://doi.org/10.1007/s00125-002-1009-0CrossRefPubMed

30.

M. Ferron, J. Lacombe, Regulation of energy metabolism by the skeleton: osteocalcin and beyond. Arch. Biochem. Biophysics 561, 137–146 (2014). https://doi.org/10.1016/j.abb.2014.05.022CrossRef

31.

A. Diaz-Lopez, M. Bullo, M. Juanola-Falgarona, M.A. Martinez-Gonzalez, R. Estruch, M.I. Covas, F. Aros, J. Salas-Salvado, Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J. Clin. Endocrinol. Metab. 98(11), 4524–4531 (2013). https://doi.org/10.1210/jc.2013-2472CrossRefPubMed

32.

K. Mori, M. Emoto, K. Motoyama, E. Lee, S. Yamada, T. Morioka, Y. Imanishi, T. Shoji, M. Inaba, Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus. Diabetol. Metab. Syndr. 4(1), 53 (2012). https://doi.org/10.1186/1758-5996-4-53CrossRefPubMedPubMedCentral

33.

R. Saucedo, G. Rico, G. Vega, L. Basurto, L. Cordova, R. Galvan, M. Hernandez, E. Puello, A. Zarate, Osteocalcin, under-carboxylated osteocalcin and osteopontin are not associated with gestational diabetes mellitus but are inversely associated with leptin in non-diabetic women. J. Endocrinol. Investig. 38(5), 519–526 (2015). https://doi.org/10.1007/s40618-014-0220-4CrossRef

34.

M. Ferron, J. Wei, T. Yoshizawa, A. Del Fattore, R.A. DePinho, A. Teti, P. Ducy, G. Karsenty, Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142(2), 296–308 (2010). https://doi.org/10.1016/j.cell.2010.06.003CrossRefPubMedPubMedCentral

35.

B. Lee, J. Shao, Adiponectin and energy homeostasis. Rev. Endocr. Metab. Disord. 15(2), 149–156 (2014). https://doi.org/10.1007/s11154-013-9283-3CrossRefPubMedPubMedCentral

36.

R. Ye, P.E. Scherer, Adiponectin, driver or passenger on the road to insulin sensitivity? Mol. Metab. 2(3), 133–141 (2013). https://doi.org/10.1016/j.molmet.2013.04.001CrossRefPubMedPubMedCentral

37.

X. Wu, H. Motoshima, K. Mahadev, T.J. Stalker, R. Scalia, B.J. Goldstein, Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52(6), 1355–1363 (2003)CrossRefPubMed

38.

J.J. Cao, Effects of obesity on bone metabolism. J. Orthop. Surg. Res. 6, 30 (2011). https://doi.org/10.1186/1749-799x-6-30CrossRefPubMedPubMedCentral

39.

B.A. Gower, K. Casazza, Divergent effects of obesity on bone health. J. Clin. Densitom. 16(4), 450–454 (2013). https://doi.org/10.1016/j.jocd.2013.08.010CrossRefPubMedPubMedCentral

40.

A.L. Evans, M.A. Paggiosi, R. Eastell, J.S. Walsh, Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J. Bone Miner. Res. 30(5), 920–928 (2015). https://doi.org/10.1002/jbmr.2407CrossRefPubMed

41.

J.S. Walsh, T. Vilaca, Obesity, type 2 diabetes and bone in adults. Calcif. Tissue Int. 100(5), 528–535 (2017). https://doi.org/10.1007/s00223-016-0229-0CrossRefPubMedPubMedCentral

42.

J. Wei, M. Ferron, C.J. Clarke, Y.A. Hannun, H. Jiang, W.S. Blaner, G. Karsenty, Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J. Clin. Investig. 124(4), 1–13 (2014). https://doi.org/10.1172/jci72323CrossRefPubMed

43.

C. Gagnon, A.L. Schafer, Bone health after bariatric surgery. JBMR 2(3), 121–133 (2018). https://doi.org/10.1002/jbm4.10048CrossRef

44.

C. Rousseau, S. Jean, P. Gamache, S. Lebel, F. Mac-Way, L. Biertho, L. Michou, C. Gagnon, Change in fracture risk and fracture pattern after bariatric surgery: nested case-control study. BMJ (Clin. Res. ed.) 354, i3794 (2016). https://doi.org/10.1136/bmj.i3794CrossRef

45.

E.W. Yu, M. Wewalka, S.A. Ding, D.C. Simonson, K. Foster, J.J. Holst, A. Vernon, A.B. Goldfine, F. Halperin, Effects of gastric bypass and gastric banding on bone remodeling in obese patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 101(2), 714–722 (2016). https://doi.org/10.1210/jc.2015-3437CrossRefPubMed

46.

R. Basu, J. Peterson, R. Rizza, S. Khosla, Effects of physiological variations in circulating insulin levels on bone turnover in humans. J. Clin. Endocrinol. Metab. 96(5), 1450–1455 (2011). https://doi.org/10.1210/jc.2010-2877CrossRefPubMedPubMedCentral

47.

M.M. Weivoda, C.K. Chew, D.G. Monroe, J.N. Farr, E.J. Atkinson, J.R. Geske, B. Eckhardt, B. Thicke, M. Ruan, A.J. Tweed, L.K. McCready, R.A. Rizza, A. Matveyenko, M. Kassem, T.L. Andersen, A. Vella, M.T. Drake, B.L. Clarke, M.J. Oursler, S. Khosla, Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat. Commun. 11(1), 87 (2020). https://doi.org/10.1038/s41467-019-14003-6CrossRefPubMedPubMedCentral

48.

I. Mosialou, S. Shikhel, J.M. Liu, A. Maurizi, N. Luo, Z. He, Y. Huang, H. Zong, R.A. Friedman, J. Barasch, P. Lanzano, L. Deng, R.L. Leibel, M. Rubin, T. Nickolas, W. Chung, L.M. Zeltser, K.W. Williams, J.E. Pessin, S. Kousteni, MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature 543(7645), 385–390 (2017). https://doi.org/10.1038/nature21697CrossRefPubMedPubMedCentral

49.

S. Costantini, C. Conte, Bone health in diabetes and prediabetes. World J. Diabetes 10(8), 421–445 (2019). https://doi.org/10.4239/wjd.v10.i8.421CrossRefPubMedPubMedCentral

50.

F. Gossiel, H. Altaher, D.M. Reid, C. Roux, D. Felsenberg, C.C. Gluer, R. Eastell, Bone turnover markers after the menopause: T-score approach. Bone 111, 44–48 (2018). https://doi.org/10.1016/j.bone.2018.03.016CrossRefPubMed

Title: Association between changes in bioactive osteocalcin and glucose homeostasis after biliopancreatic diversion
Authors: Anne-Frédérique Turcotte
Thomas Grenier-Larouche
Julie Lacombe
Anne-Marie Carreau
André C. Carpentier
Fabrice Mac-Way
André Tchernof
Denis Richard
Laurent Biertho
Stefane Lebel
Simon Marceau
Mathieu Ferron
Claudia Gagnon
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Bariatric Surgery
Bariatric Surgery
Insulins
Insulins
Type 2 Diabetes
Published in: Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02340-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c

Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism

MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives

The novel founder homozygous V225M mutation in the HSD17B3 gene causes aberrant splicing and XY-DSD

Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase

Indeterminate thyroid nodules. The role of 18F-FDG PET/CT in the “era” of ultrasonography risk stratification systems and new thyroid cytology classifications

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage